The evolution of initial indications for new cancer medicines authorised in Europe from 1995 to 2023

dc.rights.license	CC-BY-NC-ND
dc.contributor.advisor	Bloem, Lourens
dc.contributor.author	Nonis, Cristheena
dc.date.accessioned	2025-09-30T00:01:10Z
dc.date.available	2025-09-30T00:01:10Z
dc.date.issued	2025
dc.identifier.uri	https://studenttheses.uu.nl/handle/20.500.12932/50448
dc.description.sponsorship	Utrecht University
dc.language.iso	EN
dc.subject	Introduction: Despite the critical importance of therapeutic indications in optimising the benefit-risk balance of a medicine, thereby guiding clinical practice and ensuring patient safety, there is limited literature on how indication-setting has evolved over time and which factors have plays a role in that process. Objective: This study aimed to investigate the evolution of initial indications of cancer medicines authorized between January 1, 1995, and December 31, 2023.
dc.title	The evolution of initial indications for new cancer medicines authorised in Europe from 1995 to 2023
dc.type.content	Master Thesis
dc.rights.accessrights	Open Access
dc.subject.courseuu	Drug Innovation
dc.thesis.id	42229